EDAP TMS SA FOCL
EDAP TMS S.A. ("EDAP," the "Company," "we," "us," or "our") is a medical technology company focused on the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices.
Our legal name is EDAP TMS S.A., and our commercial name is Focal One®. We were founded in 1979 as a société anonyme organized under the laws of France for a duration of 60 years from the date of incorporation, unless extended by shareholder approval in accordance with French corporate law. We are headquartered in Vaulx-en-Velin, France and operate in the United States, Europe, Asia and the rest of the world. We are listed on The Nasdaq Global Market ("Nasdaq") under the symbol "EDAP."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M | $69.4M | — | — | — | — | — | — | — | — |
| Cost of revenue | $40.5M | $40.7M | — | — | — | — | — | — | — | — |
| Gross profit | $30.0M | $28.7M | — | — | — | — | — | — | — | — |
| R&D | $9.7M | $8.4M | — | — | — | — | — | — | — | — |
| SG&A | $17.7M | $15.2M | — | — | — | — | — | — | — | — |
| Total operating expenses | $54.7M | $51.0M | — | — | — | — | — | — | — | — |
| Operating income | -$24.7M | -$22.2M | — | — | — | — | — | — | — | — |
| Interest expense | $789.0K | $256.0K | — | — | — | — | — | — | — | — |
| Pre-tax income | -$28.8M | -$20.3M | — | — | — | — | — | — | — | — |
| Income tax | $438.0K | $313.0K | — | — | — | — | — | — | — | — |
| Net income | -$29.2M | -$20.6M | — | — | — | — | — | — | — | — |
| EPS, basic | -0.78 | -0.55 | — | — | — | — | — | — | — | — |
| EPS, diluted | -0.78 | -0.55 | — | — | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | $37.4M | $37.3M | $37.0M | $34.4M | $32.4M | $29.1M | $29.6M | $29.0M | $29.0M | $29.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.5M | $31.0M | $48.0M | — | — | — | — | — | — | — |
| Short-term investments | $0 | — | — | — | — | — | — | — | — | — |
| Receivables | $21.3M | $19.3M | — | — | — | — | — | — | — | — |
| Inventory | $12.8M | $19.2M | — | — | — | — | — | — | — | — |
| Total current assets | $57.2M | $72.6M | — | — | — | — | — | — | — | — |
| Property, plant and equipment | $9.9M | $7.6M | — | — | — | — | — | — | — | — |
| Goodwill | $2.8M | $2.5M | — | — | — | — | — | — | — | — |
| Other intangibles | $1.8M | $1.1M | — | — | — | — | — | — | — | — |
| Total assets | $79.0M | $89.4M | — | — | — | — | — | — | — | — |
| Short-term debt | $2.1M | $2.5M | — | — | — | — | — | — | — | — |
| Total current liabilities | $37.1M | $39.3M | — | — | — | — | — | — | — | — |
| Long-term debt | $15.9M | $2.2M | — | — | — | — | — | — | — | — |
| Total liabilities | $59.6M | $46.9M | — | — | — | — | — | — | — | — |
| Retained earnings | -$128.6M | -$99.4M | — | — | — | — | — | — | — | — |
| Total equity | $19.4M | $42.5M | $62.9M | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$14.7M | — | — | — | — | — | — | — | — |
| Depreciation and amortisation | $3.4M | $2.8M | — | — | — | — | — | — | — | — |
| Investing cash flow | -$5.7M | -$4.5M | — | — | — | — | — | — | — | — |
| Financing cash flow | $8.6M | $5.0M | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-060700.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $120.46B | 25.2x | 8.4% |
| LIVN | LivaNova PLC | $4.51B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $3.12B | 18.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.60B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.72B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.7x | 5.2% |
| CBLL | Ceribell, Inc. | $948.7M | — | 36.1% |